key: cord-0830716-4cbjbo7t
authors: Deeks, Jonathan J; Dinnes, Jacqueline; Takwoingi, Yemisi; Davenport, Clare; Spijker, René; Taylor-Phillips, Sian; Adriano, Ada; Beese, Sophie; Dretzke, Janine; Ferrante di Ruffano, Lavinia; Harris, Isobel M; Price, Malcolm J; Dittrich, Sabine; Emperador, Devy; Hooft, Lotty; Leeflang, Mariska MG; Van den Bruel, Ann
title: Antibody tests for identification of current and past infection with SARS‐CoV‐2
date: 2020-06-25
journal: Cochrane Database Syst Rev
DOI: 10.1002/14651858.cd013652
sha: ce221bfad6185fbb2233e31f3c69a370aedd6821
doc_id: 830716
cord_uid: 4cbjbo7t

BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus and resulting COVID‐19 pandemic present important diagnostic challenges. Several diagnostic strategies are available to identify current infection, rule out infection, identify people in need of care escalation, or to test for past infection and immune response. Serology tests to detect the presence of antibodies to SARS‐CoV‐2 aim to identify previous SARS‐CoV‐2 infection, and may help to confirm the presence of current infection. OBJECTIVES: To assess the diagnostic accuracy of antibody tests to determine if a person presenting in the community or in primary or secondary care has SARS‐CoV‐2 infection, or has previously had SARS‐CoV‐2 infection, and the accuracy of antibody tests for use in seroprevalence surveys. SEARCH METHODS: We undertook electronic searches in the Cochrane COVID‐19 Study Register and the COVID‐19 Living Evidence Database from the University of Bern, which is updated daily with published articles from PubMed and Embase and with preprints from medRxiv and bioRxiv. In addition, we checked repositories of COVID‐19 publications. We did not apply any language restrictions. We conducted searches for this review iteration up to 27 April 2020. SELECTION CRITERIA: We included test accuracy studies of any design that evaluated antibody tests (including enzyme‐linked immunosorbent assays, chemiluminescence immunoassays, and lateral flow assays) in people suspected of current or previous SARS‐CoV‐2 infection, or where tests were used to screen for infection. We also included studies of people either known to have, or not to have SARS‐CoV‐2 infection. We included all reference standards to define the presence or absence of SARS‐CoV‐2 (including reverse transcription polymerase chain reaction tests (RT‐PCR) and clinical diagnostic criteria). DATA COLLECTION AND ANALYSIS: We assessed possible bias and applicability of the studies using the QUADAS‐2 tool. We extracted 2x2 contingency table data and present sensitivity and specificity for each antibody (or combination of antibodies) using paired forest plots. We pooled data using random‐effects logistic regression where appropriate, stratifying by time since post‐symptom onset. We tabulated available data by test manufacturer. We have presented uncertainty in estimates of sensitivity and specificity using 95% confidence intervals (CIs). MAIN RESULTS: We included 57 publications reporting on a total of 54 study cohorts with 15,976 samples, of which 8526 were from cases of SARS‐CoV‐2 infection. Studies were conducted in Asia (n = 38), Europe (n = 15), and the USA and China (n = 1). We identified data from 25 commercial tests and numerous in‐house assays, a small fraction of the 279 antibody assays listed by the Foundation for Innovative Diagnostics. More than half (n = 28) of the studies included were only available as preprints. We had concerns about risk of bias and applicability. Common issues were use of multi‐group designs (n = 29), inclusion of only COVID‐19 cases (n = 19), lack of blinding of the index test (n = 49) and reference standard (n = 29), differential verification (n = 22), and the lack of clarity about participant numbers, characteristics and study exclusions (n = 47). Most studies (n = 44) only included people hospitalised due to suspected or confirmed COVID‐19 infection. There were no studies exclusively in asymptomatic participants. Two‐thirds of the studies (n = 33) defined COVID‐19 cases based on RT‐PCR results alone, ignoring the potential for false‐negative RT‐PCR results. We observed evidence of selective publication of study findings through omission of the identity of tests (n = 5). We observed substantial heterogeneity in sensitivities of IgA, IgM and IgG antibodies, or combinations thereof, for results aggregated across different time periods post‐symptom onset (range 0% to 100% for all target antibodies). We thus based the main results of the review on the 38 studies that stratified results by time since symptom onset. The numbers of individuals contributing data within each study each week are small and are usually not based on tracking the same groups of patients over time. Pooled results for IgG, IgM, IgA, total antibodies and IgG/IgM all showed low sensitivity during the first week since onset of symptoms (all less than 30.1%), rising in the second week and reaching their highest values in the third week. The combination of IgG/IgM had a sensitivity of 30.1% (95% CI 21.4 to 40.7) for 1 to 7 days, 72.2% (95% CI 63.5 to 79.5) for 8 to 14 days, 91.4% (95% CI 87.0 to 94.4) for 15 to 21 days. Estimates of accuracy beyond three weeks are based on smaller sample sizes and fewer studies. For 21 to 35 days, pooled sensitivities for IgG/IgM were 96.0% (95% CI 90.6 to 98.3). There are insufficient studies to estimate sensitivity of tests beyond 35 days post‐symptom onset. Summary specificities (provided in 35 studies) exceeded 98% for all target antibodies with confidence intervals no more than 2 percentage points wide. False‐positive results were more common where COVID‐19 had been suspected and ruled out, but numbers were small and the difference was within the range expected by chance. Assuming a prevalence of 50%, a value considered possible in healthcare workers who have suffered respiratory symptoms, we would anticipate that 43 (28 to 65) would be missed and 7 (3 to 14) would be falsely positive in 1000 people undergoing IgG/IgM testing at days 15 to 21 post‐symptom onset. At a prevalence of 20%, a likely value in surveys in high‐risk settings, 17 (11 to 26) would be missed per 1000 people tested and 10 (5 to 22) would be falsely positive. At a lower prevalence of 5%, a likely value in national surveys, 4 (3 to 7) would be missed per 1000 tested, and 12 (6 to 27) would be falsely positive. Analyses showed small differences in sensitivity between assay type, but methodological concerns and sparse data prevent comparisons between test brands. AUTHORS' CONCLUSIONS: The sensitivity of antibody tests is too low in the first week since symptom onset to have a primary role for the diagnosis of COVID‐19, but they may still have a role complementing other testing in individuals presenting later, when RT‐PCR tests are negative, or are not done. Antibody tests are likely to have a useful role for detecting previous SARS‐CoV‐2 infection if used 15 or more days after the onset of symptoms. However, the duration of antibody rises is currently unknown, and we found very little data beyond 35 days post‐symptom onset. We are therefore uncertain about the utility of these tests for seroprevalence surveys for public health management purposes. Concerns about high risk of bias and applicability make it likely that the accuracy of tests when used in clinical care will be lower than reported in the included studies. Sensitivity has mainly been evaluated in hospitalised patients, so it is unclear whether the tests are able to detect lower antibody levels likely seen with milder and asymptomatic COVID‐19 disease. The design, execution and reporting of studies of the accuracy of COVID‐19 tests requires considerable improvement. Studies must report data on sensitivity disaggregated by time since onset of symptoms. COVID‐19‐positive cases who are RT‐PCR‐negative should be included as well as those confirmed RT‐PCR, in accordance with the World Health Organization (WHO) and China National Health Commission of the People's Republic of China (CDC) case definitions. We were only able to obtain data from a small proportion of available tests, and action is needed to ensure that all results of test evaluations are available in the public domain to prevent selective reporting. This is a fast‐moving field and we plan ongoing updates of this living systematic review.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and resulting COVID-19 pandemic present important diagnostic challenges. Several diagnostic strategies are available to identify current infection, rule out infection, identify people in need of care escalation, or to test for past infection and immune response. Serology tests to detect the presence of antibodies to SARS-CoV-2 aim to identify previous SARS-CoV-2 infection, and may help to confirm the presence of current infection.

To assess the diagnostic accuracy of antibody tests to determine if a person presenting in the community or in primary or secondary care has SARS-CoV-2 infection, or has previously had SARS-CoV-2 infection, and the accuracy of antibody tests for use in seroprevalence surveys.

We undertook electronic searches in the Cochrane COVID-19 Study Register and the COVID-19 Living Evidence Database from the University of Bern, which is updated daily with published articles from PubMed and Embase and with preprints from medRxiv and bioRxiv. In addition, we checked repositories of COVID-19 publications. We did not apply any language restrictions. We conducted searches for this review iteration up to 27 April 2020.

Background COVID-19 is an infectious disease caused by the SARS-CoV-2 virus that spreads easily between people in a similar way to the common cold or 'flu. Most people with COVID-19 have a mild to moderate respiratory illness, and some may have no symptoms (asymptomatic infection).

Others experience severe symptoms and need specialist treatment and intensive care.

The immune system of people who have COVID-19 responds to infection by developing proteins that can attack the virus (antibodies) in their blood. Tests to detect antibodies in peoples' blood might show whether they currently have COVID-19 or have had it previously.

Accurate testing allows identification of people who might need treatment, or who need to isolate themselves to prevent the spread of infection. Failure to detect people with COVID-19 when it is present (a false negative result) may delay treatment and risk further spread of infection to others. Incorrect identification of COVID-19 when it is not present (a false positive result) may lead to unnecessary further testing, treatment, and isolation of the person and close contacts. Correct identification of people who have previously had COVID-19 is important in measuring disease spread, assessing the success of public health interventions (like isolation), and potentially in identifying individuals with immunity (should antibodies in the future be shown to indicate immunity).

To identify false negative and false positive results, antibody test results are compared in people known to have COVID-19 and known not to have . Study participants are classified as to whether they are known or not known to have COVID-19 based on criteria known as the 'reference standard'. Many studies use samples taken from the nose and throat to identify people with COVID-19. The samples undergo a test called reverse transcriptase polymerase chain reaction (RT-PCR). This testing process can sometimes miss infection (false negative result), but additional tests can identify COVID-19 infection in people with a negative RT-PCR result. These include measuring clinical symptoms, like coughing or high temperature, or 'imaging' tests like chest X-rays. People known not to have COVID-19 are sometimes identified from stored blood samples taken before COVID-19 existed, or from patients with respiratory symptoms found to be caused by other diseases.

The studies looked at three types of antibody, IgA, IgG and IgM. Most tests measure both IgG and IgM, but some measure a single antibody or combinations of the three antibodies.

Levels of antibodies rise and fall at di erent times a er infection. IgG is the last to rise but lasts longest. Levels of antibodies are usually highest a few weeks a er infection.

Some antibody tests need specialist laboratory equipment. Others use disposable devices, similar to pregnancy tests. These tests can be used in laboratories or wherever the patient is (point-of-care), in hospital or at home.

We wanted to find out whether antibody tests:

-are accurate enough to diagnose infection in people with or without symptoms of COVID-19, and -can be used to find out if someone has already had COVID-19.

We looked for studies that measured the accuracy of antibody tests compared with reference standard criteria to detect current or past COVID-19 infection. Studies could assess any antibody test compared with any reference standard. People could be tested in hospital or the community. Studies could test people known to have -or not to have -or be suspected of having COVID-19.

-58 people would test positive for COVID-19. Of these, 12 people (21%) would not have COVID-19 (false positive result).

-942 people would test negative for COVID-19. Of these, 4 people (0.4%) would actually have COVID-19 (false negative result).

If we tested 1000 healthcare workers (in a high-risk setting) who had had symptoms, and 500 (50%) of them really had COVID-19:

-464 people would test positive for COVID-19. Of these, 7 people (2%) would not have COVID-19 (false positive result).

-537 people would test negative for COVID-19. Of these, 43 (8%) would actually have COVID-19 (false negative result).

We did not find convincing di erences in accuracy for di erent types of antibody test.

Our confidence in the evidence is limited for several reasons. In general, studies were small, did not use the most reliable methods and did not report their results fully. O en, they did not include patients with COVID-19 who may have had a false negative result on PCR, and took their data for people without COVID-19 from records of tests done before COVID-19 arose. This may have a ected test accuracy, but it is impossible to identify by how much.

Most participants were in hospital with COVID-19, so were likely to have more severe disease than people with mild symptoms who were not hospitalised. This means that we don't know how accurate antibody tests are for people with milder disease or no symptoms.

More than half of the studies assessed tests they had developed themselves, most of which are not available to buy. Many studies were published quickly online as 'preprints'. Preprints do not undergo the normal rigorous checks of published studies, so we are not certain how reliable they are.

As most studies took place in Asia, we don't know whether test results would be similar elsewhere in the world.

The review shows that antibody tests could have a useful role in detecting if someone has had COVID-19, but the timing of when the tests are used is important. Antibody tests may help to confirm COVID-19 infection in people who have had symptoms for more than two weeks and do not have a RT-PCR test, or have negative RT-PCR test results. The tests are better at detecting COVID-19 in people two or more weeks a er their symptoms started, but we do not know how well they work more than five weeks a er symptoms started. We do not know how well the tests work for people who have milder disease or no symptoms, because the studies in the review were mainly done in people who were in hospital. In time, we will learn whether having previously had COVID-19 provides individuals with immunity to future infection.

Further research is needed into the use of antibody tests in people recovering from COVID-19 infection, and in people who have experienced mild symptoms or who never experienced symptoms.

Question What is the diagnostic accuracy of antibody tests, for the diagnosis of current or prior SARS-CoV-2 infection?

Adults or children suspected of

• current SARS-CoV-2 infection • prior SARS-CoV-2 infection or populations undergoing screening for SARS-CoV-2 infection, including

• asymptomatic contacts of confirmed COVID-19 cases • community screening

Any test for detecting antibodies to SARS-CoV-2, including:

• laboratory-based methods * ELISA * CLIA * other laboratory-based methods • rapid tests; lateral flow assays, including * tests that can be used at point-of-care, such as CGIA * rapid diagnostic tests, such as FIA

Detection of Cochrane Database of Systematic Reviews

• We included 54 studies evaluating 15,976 samples. 8256 samples were from COVID-19 cases.

• Data were not available for most antibody tests that have regulatory approval.

• Most studies reported on detection of IgG, IgM, or IgG/IgM antibodies.

• Test sensitivity was strongly related to time since onset of symptoms, with low sensitivity between 1 and 14 days, and sensitivity for IgG/IgM tests exceeding 90% between 15 and 35 days. Little evidence was available beyond 35 days. • Specificity was high (> 98%) for all types of antibody. There was some variation in sensitivity between test methods, with laboratory-based methods appearing to outperform (point-of-care) tests using disposable devices. • Small sample sizes, low numbers of studies and concerns and bias and applicability hinder trustworthy comparisons being made between test brands. 

Days 

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and resulting COVID-19 pandemic present important diagnostic evaluation challenges. These range from understanding the value of signs and symptoms in predicting possible infection, assessing whether existing biochemical and imaging tests can identify infection and people needing critical care, and evaluating whether new diagnostic tests can allow accurate rapid and point-ofcare testing, either to identify current infection, rule out infection, identify people in need of care escalation, or to test for past infection and immunity.

We are creating and maintaining a suite of living systematic reviews to cover the roles of tests and characteristics in the diagnosis of COVID-19. This review summarises evidence of the accuracy of COVID-19 antibody tests; both laboratory-based tests and point-ofcare tests.

COVID-19 is the disease caused by infection with the SARS-CoV-2 virus. The key target conditions for this suite of reviews are current SARS-CoV-2 infection, current COVID-19 disease, and past SARS-CoV-2 infection.

Antibody tests are being considered and evaluated for both:

• identification of past SARS-CoV-2 infection, and • current infection.

For current infection the severity of the disease is of importance. SARS-CoV-2 infection can be asymptomatic (no symptoms); mild or moderate (symptoms such as fever, cough, aches, lethargy but without di iculty breathing at rest); severe (symptoms with breathlessness and increased respiratory rate indicative of pneumonia); or critical (requiring respiratory support due to severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS). People with COVID-19 pneumonia (severe or critical disease) require di erent patient management, and it is important to be able to identify them. There is no consideration that antibody tests are able to distinguish severity of disease, thus, in this review, we consider their role for detecting SARS-CoV-2 infection of any severity (asymptomatic or symptomatic).

This review evaluates serology tests to measure antibodies to the SARS-CoV-2 virus. Antibodies are formed by the body's immune system in response to infections, and can be detected in whole blood, plasma or serum. Antibodies are specific to the virus, and therefore can be used to di erentiate between di erent infections. There are three types of antibody created in response to infection: IgA, IgG and IgM; these rise and fall at di erent times a er the onset of infection. IgG is used in most antibody tests as it persists for the longest time and may reflect longer-term immunity, although it is the last to rise a er infection. Many tests assess both IgG and IgM. IgM typically rises quickly with infection and declines soon a er an infection is cleared. Alternatively tests may combine IgA with IgG, or measure all antibodies (IgA, IgG and IgM).

Antibody tests are available for laboratory use including enzyme-linked immunosorbent assay (ELISA) methods, or more advanced chemiluminescence immunoassays (CLIA). There are also laboratory-independent, point-of-care lateral flow assays, which use disposable devices, akin to a pregnancy test, that use a minimal amount of blood on a testing strip. Antibody detection is indicated by visible lines appearing on the test strip, or through fluorescence, which can be detected using a reader device. Many of these tests are known as colloidal gold-based immunoassays, as they use COVID-19 antigen conjugated to gold nanoparticles.

Following the emergence of COVID-19 there has been prolific industry activity to develop accurate antibody tests. The Foundation for Innovative Diagnostics (FIND) and Johns Hopkins Centre for Health Security have maintained online lists of these and other molecular-based tests for COVID-19. At the time of writing (21 May 2020), FIND listed 279 antibody tests, 196 of which are produced by commercial companies and are commercially available. Reguatory approval in the European Union (EU; CE-IVD) had been awarded to 185 on the list, whereas in China only seven had been approved, and eight by the FDA (US Food and Drug Administration). For a period of time the FDA allowed commercialisation of antibody tests in the USA without FDA approval, resulting in around 100 tests being placed on the market. Both the content of the list, and these figures will increase over time.

Broadly speaking, there are four considered uses of antibody tests.

1. In diagnosis of acute suspected COVID-19 in patients who presented with symptoms, particularly where molecular testing had failed to detect the virus. 2. In assessment of immune response in patients with severe disease. 3. For individuals to assess whether they have had a SARS-CoV-2 infection and have an immune response. 4. In seroprevalence surveys for public health management purposes.

For 1, the standard approach to diagnosis of COVID-19 is through a reverse transcription polymerase chain reaction (RT-PCR) test, which detects the presence of virus in swab samples taken from nose, throat or fluid from the lungs. However, the test is known to give false negative results, and can only detect COVID-19 in the acute phase of the illness. Both the World Health Organization (WHO) and the China CDC (National Health Commission of the People's Republic of China), have produced case definitions for COVID-19 that include RT-PCR-negative cases that display other convincing clinical evidence (Appendix 1). The most recent case definition from the China CDC includes positive serology tests.

Confirming an acute clinical diagnosis using a serology test requires detectable virus-specific IgM and IgG in serum, or detectable virusspecific IgG, or a 4-fold or greater increase in titration to be observed during convalescence compared with the acute phase.

For 2, this is largely a question of monitoring patients, and we will not cover this in this review. Assessment of the accuracy of a test used for assessment of immune response would involve comparison with a reference standard test of antibody response, rather than evidence of infection.

Trusted evidence. Informed decisions. Better health.

Use 3 involves testing individuals during periods of convalescence (a er symptoms have resolved) whereas 4 will involve testing people at a mixture of time points, including long follow-up. A key di erence between 3 and 4 is the likelihood of disease, which is expected to be much higher for 3 than 4.

An extended version of use case scenarios is available in Appendix 2.

Prior testing depends on the purpose of the test. For 1 we would anticipate that patients were symptomatic and had most likely undergone RT-PCR testing and possible computed tomography (CT) imaging. Uses 3 and 4 will most likely include people who have not been tested, and may include people who are asymptomatic as well as symptomatic.

This review is one of six planned reviews that cover the range of tests and characteristics being considered in the management of COVID-19 (Deeks 2020; McInnes 2020) . Full details of the alternative tests and evidence of their accuracy will be summarised in these reviews.

Testing for presence of the SARS-CoV-2 virus has been undertaken using quantitative RT-PCR (qRT-PCR). RT-PCR tests for SARS-CoV-2 identify viral ribonucleic acid (RNA). Reagents for the assay were rapidly produced once the viral RNA sequence was published. Testing is undertaken in central laboratories and can be very labourintensive, with several points along the path of performing a single test where errors may occur, although some automation of parts of the process is possible. Although the actual qRT-PCR test does not take long, the stages of extraction, sample processing and data management mean that test results are typically available in 24 to 48 hours, although faster processes are being implemented. Other nucleic acid amplification methods such as loop-mediated isothermal amplification (LAMP), or CRISPR-based nucleic acid detection methods are also being developed, with the potential to reduce the time to produce test results to minutes, but the time for the whole process may still be significant. RT-PCR tests use upper and lower respiratory samples. Sputum is currently considered better than oropharynx swabs or nasopharynx swabs but is more di icult (and hazardous) to obtain and will only ever be available in a subset of patients.

Laboratory-independent RT-PCR devices can also be used for identification of infection near patients and even at the bedside. These are small platforms for testing which use matching test cartridges. Several companies have suitable existing technology systems and are producing the required new cartridges for diagnosis of SARS-CoV-2 infection. Test results are based on the same samples as those for qRT-PCR, with results available within minutes or hours. Antigen tests are based on the direct detection of the virus, indicating active infection (i.e. replication of the virus) similar to the detection of RNA. Antigen tests are mainly in the form of lateral flow assays. They will capture the relevant viral antigen using dedicated antibodies, and visualisation is either manual or using a reader device.

Signs and symptoms are used in the initial diagnosis of suspected COVID-19, and in identifying people with COVID-19 pneumonia. Key symptoms that have been associated with mild to moderate COVID-19 include: troublesome dry cough (for example, coughing more than usual over a one-hour period, or three or more coughing episodes in 24 hours), fever greater than 37.8°C, diarrhoea, headache, breathlessness on light exertion, muscle pain, fatigue, and loss of sense of smell and taste. Red flags indicating possible pneumonia include: breathlessness at rest, increased respiratory rate (above 20 breaths per minute), increased heart rate (above 100 beats per minute), chest tightness, loss of appetite, confusion, pain or pressure in the chest, blue lips or face, and temperature above 38°C. Hypoxia based on measuring pulse oximetry is o en used, with various arbitrary thresholds (for example, 93%).

Routinely available biomarkers for infection and inflammation may be considered in the investigation of people with possible COVID-19. For example, many healthcare facilities have access to standard laboratory tests for infection, such as C-reactive protein (CRP), procalcitonin, measures of anticoagulation, and white blood cell count with di erent lymphocyte subsets. Evaluation of these commonly available tests, particularly in low-resource settings, may be helpful for the triage of people with potential COVID-19.

Chest X-ray, ultrasound, and CT are widely used diagnostic imaging tests to identify COVID-19 pneumonia. Availability and usage varies between settings.

It is essential to understand the clinical accuracy of tests and diagnostic features to identify the best way they can be used in di erent settings to develop e ective diagnostic and management pathways. The suite of Cochrane 'living systematic reviews' summarises evidence on the clinical accuracy of di erent tests and diagnostic features, grouped according to the research questions and settings that we are aware of. Estimates of accuracy from these reviews will help inform diagnosis, screening, isolation, and patient management decisions.

Particularly for antibody tests, new tests are being developed and evidence is emerging at an unprecedented rate during the COVID-19 pandemic. Tests are being purchased in bulk for seroprevalence studies, and made available for personal purchase online. This review will be updated as o en as is feasible to ensure that it provides current evidence about the accuracy of antibody tests.

To assess the diagnostic accuracy of antibody tests to determine if a person presenting in the community or in primary or secondary care has SARS-CoV-2 infection, or has previously had SARS-CoV-2 infection, and the accuracy of antibody tests for use in seroprevalence surveys.

Trusted evidence. Informed decisions. Better health.

• current infection or past infection;

• test method and brand;

• days since onset of symptoms;

• reference standard;

• study design;

• setting.

Criteria for considering studies for this review

We applied broad eligibility criteria in order to include all patient groups and all variations of a test (that is, if patient population was unclear, we included the study).

We included studies of all designs that produce estimates of test accuracy or provide data from which estimates can be computed, including the following.

• Studies restricted to participants confirmed to have (or to have had) the target condition (to estimate sensitivity) or confirmed not to have (or have had) the target condition (to estimate specificity). These types of studies may be excluded in later review updates. • Single-group studies, which recruit participants before disease status has been ascertained • Multi-group studies, where people with and without the target condition are recruited separately (o en referred to as two-gate or diagnostic case-control studies) • Studies based on either patients or samples

We excluded studies from which we could not extract data to compute either sensitivity or specificity.

We carefully considered the limitations of di erent study designs in the quality assessment and analyses.

We included studies reported in published articles and as preprints.

We included studies recruiting people presenting with suspicion of current or prior SARS-CoV-2 infection or those recruiting populations where tests were used to screen for disease (for example, contact tracing or community screening).

We also included studies that recruited people either known to have SARS-CoV-2 infection or known not to have SARS-CoV-2 infection (multi-group studies).

We excluded small studies with fewer than 10 samples or participants. Although the size threshold of 10 is arbitrary, such small studies are likely to give unreliable estimates of sensitivity or specificity and may be biased.

We included studies evaluating any test for detecting antibodies to SARS-CoV-2, including laboratory-based methods and tests designed to be used at point-of-care. Test methods include the following.

• enzyme-linked immunosorbent assays (ELISA) • chemiluminescence immunoassays (CLIA) • other laboratory-based methods (e.g. indirect immunofluorescence tests (IIFT), luciferase immunoprecipitation system (LIPS) Rapid diagnostic tests:

• lateral flow assays, including both colloidal gold or fluorescence-labelled immunochromatographic assays (CGIA or FIA) .

In this first version of the review we have included both commercially available tests, which have regulatory approval, with in-house assays and assays in development. Future versions of the review are likely to be restricted to only commercially available assays.

We identified the regulatory status of index tests using two main resources:

• WHO: COVID-19 listing in International Medical Device Regulators Forum (IMDRF) jurisdictions (www.who.int/ diagnostics_laboratory/EUL/en/), which includes listings of FDA, Health Canada, Japan, Australia (Therapeutic Goods Administration), Singapore (Health Sciences Authority), Brazil (Agência Nacional de Vigilância Sanitária), South Korea (Ministry of Food and Drug Safety), China (National Medical Products Administration), and Russia (Roszdravnadzor); • FIND: SARS-COV-2 Diagnostic Pipeline (www.finddx.org/ covid-19/pipeline/), which overlaps with the WHO list, but in addition includes CE-IVD and IVD India.

In addition, we checked key national websites, including US FDA (www.fda.gov/medical-devices/emergency-situationsmedical-devices/emergency-use-authorizations#coronavirus2019) and China FDA (subsites.chinadaily.com.cn/nmpa/2020 03/27/c_465663.htm? bsh_bid=5496527208).

The target conditions were the identification of:

• current SARS-CoV-2 infection (in symptomatic cases); • past SARS-CoV-2 infection (in convalescent (post-symptomatic) or asymptomatic cases).

We anticipated that studies would use a range of reference standards to define both the presence and absence of SARS-CoV-2 infection but were unclear at the start of the review exactly what methods would be encountered. For the QUADAS-2 (Quality Assessment tool for Diagnostic Accuracy Studies; Whiting 2011), assessment we categorised each method of defining COVID-19 cases according to the risk of bias (the chances that it would misclassify COVID-19 participants as non-COVID-19) and whether it defined COVID-19 in an appropriate way that reflected cases encountered in practice. Likewise, we considered the risk of bias in definitions of non-COVID-19, and whether the definition reflected those who, in practice, would be tested.

We conducted electronic searches using two primary sources. Both of these searches aimed to identify all published articles and preprints related to COVID-19, and were not restricted to those evaluating biomarkers or tests. Thus, there are no test terms, diagnosis terms, or methodological terms in the searches. Searches were limited to 2019 and 2020, and for this version of the review have been conducted to 27 April 2020.

We used the Cochrane COVID-19 Study Register (covid-19.cochrane.org/), for searches conducted to 28 March 2020. At that time, the register was populated by searches of PubMed, as well as trials registers at ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP).

Search strategies were designed for maximum sensitivity, to retrieve all human studies on COVID-19 and with no language limits. See Appendix 3.

From 28 March 2020, we used the COVID-19 Living Evidence database from the Institute of Social and Preventive Medicine (ISPM) at the University of Bern (www.ispm.unibe.ch), as the primary source of records for the Cochrane COVID-19 DTA reviews. This search includes PubMed, Embase, and preprints indexed in bioRxiv and medRxiv databases. The strategies as described on the ISPM website are described here (ispmbern.github.io/covid-19/). See Appendix 4.

The decision to focus primarily on the 'Bern' feed was due to the exceptionally large numbers of COVID-19 studies available only as preprints. The Cochrane COVID-19 Study Register has undergone a number of iterations since the end of March and we anticipate moving back to the Register as the primary source of records for subsequent review updates.

We In addition we have used the list of potentially eligible index tests (documented in Criteria for considering studies for this review), to search company and product websites for studies about test accuracy and to contact companies to request further information or studies using their tests. We will include the result of this process in a future iteration of this review.

We have also contacted research groups undertaking test evaluations (for example, UK Public Health England-funded studies, and FIND studies (www.finddx.org/). We appeal to researchers to supply details of additional published or unpublished studies at the following email address, which we will consider for inclusion in future updates (coviddta@contacts.bham.ac.uk).

We did not apply any language restrictions.

A team of experienced systematic reviewers from the University of Birmingham screened the titles and abstracts of all records retrieved from the literature searches. Two review authors independently screened studies in Covidence. A third, senior review author resolved any disagreements. We tagged all records selected as potentially eligible according to the Cochrane COVID-19 DTA review(s) that they might be eligible for and we then exported them to separate Covidence reviews for each review title.

We obtained the full texts for all studies flagged as potentially eligible. Two review authors independently screened the full texts for one of the COVID-19 molecular or antibody test reviews. We resolved any disagreements on study inclusion through discussion with a third review author.

One review author carried out data extraction, which was checked by a second review author. Items that we extracted are listed in Appendix 6. Both review authors independently performed data extraction of 2x2 contingency tables of the number of true positives, false positives, false negatives and true negatives. They resolved disagreements by discussion.

We encourage study authors to contact us regarding missing details on the included studies (coviddta@contacts.bham.ac.uk).

Where possible we extracted 2x2 tables according to time since onset of symptoms. We predefined groups of interest as 1-7, 8-14, 15-21, 22-35 and over 35 days since onset of symptoms. Where the data presented did not exactly match these categorisations we entered data in the time group that had the greatest overlap with our groupings. Where a study presented data for a group without stating an upper time limit (e.g. more than 21 days) we placed the data in the first category above the stated value (e.g. 22-35 days).

Where possible, we separately extracted data related to each class of antibody (IgA, IgG and IgM), and combinations of classes (IgA/ Cochrane Database of Systematic Reviews IgM, IgA/IgG, IgG/IgM, where a positive is defined as either or both classes of antibody being detected). We also extracted data on total antibodies where this was reported.

Two review authors independently assessed risk of bias and applicability concerns using the QUADAS-2 checklist tailored to this review (Appendix 7; Whiting 2011). The two review authors resolved any disagreements by discussion.

Ideally, studies should prospectively recruit a representative sample of participants presenting with signs and symptoms of COVID-19, either in community or primary care settings or to a hospital setting, and they should clearly record the time of testing a er the onset of symptoms. 

We grouped data by study and test. Thus studies that evaluated multiple tests in the same participants were included multiple times. We present estimates of sensitivity and specificity for each antibody (or combination of antibodies) using paired forest plots in tables, and also summarise them in tables as appropriate.

For analysis purposes, unlike in most DTA reviews we considered estimates of sensitivity and specificity separately, because many of the included studies presented only estimates of sensitivity. Estimates of specificity were typically exceptionally high, thus the correlation between sensitivity and specificity across studies was unlikely to be high (Macaskill 2010; Takwoingi 2017). We considered the heterogeneity in the study findings through visual inspection of forest plots when deciding to meta-analyse study estimates, and have not computed summary estimates where they were likely to be regarded as misleading.

Where we pooled results, we fitted random-e ects logistic regression models using the meqrlogit command in Stata v15.1 (Stata). In a small number of instances, the random-e ects logistic regression analyses failed to converge (usually when there were very small numbers of studies), and we have computed estimates and confidence intervals by summing the counts of true positive, false positive, false negative and true negative across 2x2 tables. These analyses are clearly marked in the tables. We present all estimates with 95% confidence intervals.

We investigated sources of heterogeneity in two ways. First, for analysis of sensitivity for time since onset of symptoms, we extracted data by week and extended the random-e ects logistic regression model to include indicator variables for each week.

There was a strong relationship between time since onset of symptoms and sensitivity, thus we elected to fit all subsequent models for investigation of heterogeneity in sensitivity stratifying by week. We excluded studies for which stratified data were not available at this stage. For analysis of sensitivity according to the RT-PCR status of patients (RT-PCR positive 'confirmed' and RT-PCR negative 'suspect'), we extracted 2x2 tables stratified by RT-PCR result (as well as week) and extended the random-e ects logistic regression to include terms for week and RT-PCR status.

We investigated heterogeneity related to study design, reference standard and test technology by including indicator variables in the random-e ects logistic regression model alongside the variables for week since onset of symptoms. We present estimates from these models by test or reference standard type for the sensitivity of the test in the third week since onset of symptoms (since this is the time point most commonly recommended for post-infection testing to start to be undertaken).

We did not fit models to compare test brands due to the small number of studies available, but we do report estimates with confidence intervals for each brand.

We planned to undertake sensitivity analyses by excluding:

• unpublished studies;

• studies identified only from industry 'Instructions for use' documentation; • studies using sample banks or spiked samples;

• studies with inadequate reference standards;

• for previous infection, we also planned to assess increasing lengths of time since symptoms cleared.

In this version of the review we did not undertake any of these analyses because the majority of studies were preprints, we did not include any company documents, and no study used spiked samples. We investigated issues with reference standards and time as part of the investigations of heterogeneity.

We made no formal assessment of reporting bias. However we were aware of the manner in which results in studies could be suppressed by test developers or manufacturers, and detail where we believe this may have happened.

We are aware that a substantial number of studies have been published since the search date of 27 April 2020 and plan to update this review imminently. We have already completed searches for the update up until 25 May 2020, and report the number of studies that we anticipate will be added to this review in the first update.

We screened 10,965 unique references (published or preprints) for inclusion in the complete suite of reviews to assist in the diagnosis of COVID-19 (Deeks 2020; McInnes 2020) . Of 1430 records selected for further assessment for inclusion in any of the six reviews, we assessed 267 full-text reports for inclusion in this review. See Figure  1 for the PRISMA flow diagram of search and eligibility results (McInnes 2018; Moher 2009) . We included 54 studies from 57 reports in this review, three studies are awaiting assessment including two foreign language papers and one study of neutralising antibodies (Characteristics of studies awaiting classification), 34 are ongoing studies (Characteristics of ongoing studies), and we excluded 172 publications. Exclusions were mainly due to ineligible study designs (n = 84) or index tests (n = 40), or because we could not extract or reconstruct 2x2 data (n = 21). The reasons for exclusion of all 172 publications are provided in Characteristics of excluded studies.

The 57 included study reports relate to 54 separate studies, six studies (Gao 2020a; Liu 2020d [A] ; Pan 2020a; Okba 2020a; Wang 2020a [A] ; Zhao 2020a), having two publications each, and three studies providing data for two separate cohorts of participants (Cassaniti 2020 (A) ; Cassaniti 2020 (B) ; Garcia 2020 (A); Garcia 2020 (B) ; Long 2020 (A); Long 2020 (B) ). Of the 57 study reports, 28 studies are available only as preprints and four as preprints with subsequent journal publications. (Please note when naming studies, we use the letters (A), (B) , (C) in standard brackets to indicate multiple studies from the same publication, and the letters [A] , [B] , [C] etc. in square brackets to indicate data on di erent tests evaluated in the same study).

The 54 studies include a total of 15,976 samples, with 8526 samples from cases of COVID-19. Summary study characteristics are presented in Table 1 with further details of study design and index test details in Appendix 8 and Appendix 9. The median sample size across the included studies is 129.5 (interquartile range (IQR) 57 to 347) and median number of COVID-19 cases included is 62 (IQR 31 to 151). Thirty-eight studies were conducted in Asia: China (n = 36); Hong Kong (n = 1); or Singapore (n = 1). Fi een studies were conducted in Europe, and the remaining study included samples from more than one country (Bendavid 2020). Forty-four studies included only hospital inpatient cases, one included hospital outpatients, two included participants attending emergency departments, two, community screening (including one study of close contacts). Five studies were conducted in mixed or unclear settings.

Twenty-three studies included cases during the early phase of illness only (< 21 days post-symptom onset), two only included cases 21 days or more post-symptom onset, 23 included mixed groups and six did not report days post-symptom onset. Few studies were clear whether participants were symptomatic or convalescent (i.e. symptoms had resolved) at the time of testing. It is therefore di icult to clearly separate out studies that detected current infection from studies that detected past infection. Thus the two target conditions we defined cannot clearly be distinguished. There were no studies exclusively in asymptomatic participants.

The mean or median age of included COVID-19 cases ranges from 37 to 76 years (reported in 31 studies), and 26% to 87% of participants were male (reported in 31 studies). Full details are in the Characteristics of included studies table.

We identified six studies that recruited suspected COVID-19 cases before it was ascertained whether the patients did or did not have COVID-19. These six studies identified people with suspected COVID-19 based on symptoms or as close contacts of confirmed cases (symptomatic and asymptomatic). Sample sizes of these studies ranged from 50 to 814 with between 3 and 154 COVID-19 cases. Four of these studies defined the presence or absence of COVID-19 based on RT-PCR alone, and two also included clinically confirmed RT-PCR-negative cases based on undefined clinical suspicion or CT findings. The absence of SARS-CoV-2 infection was confirmed by a single RT-PCR-negative result in five of the six and by two or more negative RT-PCR results in one study.

The other forty-eight studies retrospectively recruited patients when it was already known whether or not they had COVID-19.

Twenty-nine studies used two-or multi-group study designs with separate selection of COVID-19 cases and healthy participants or non-COVID-19 participants with another disease. Sample sizes ranged from 17 to 3481 with between 7 and 276 COVID-19 cases. Nineteen of these studies defined COVID-19 cases based on a positive RT-PCR test, six included clinically defined RT-PCR-negative cases in addition to RT-PCR-positive cases and the remaining four studies used mixed or unclear criteria to define the presence of COVID-19. Four of the 29 studies included participants with suspected COVID-19 but who had subsequently been ruled out on the basis of one (2 studies) or more (2 studies) negative RT-PCR tests. Ten included contemporaneous non-COVID-19 groups, including samples from healthy participants (5 studies), patients with other diseases (one study) or both (4 studies), only two of which used RT-PCR testing to exclude the presence of SARS-CoV-2. Twelve studies included pre-pandemic non-COVID 19 groups, using samples from either healthy people (n = 5), participants with other diseases (n = 3), or both (n = 4). The remaining three studies included control samples from mixed sources including pre- Nineteen studies included only a single group of only COVID-19 cases, thus only allowing estimation of sensitivity. They determined COVID-19 cases based on positive RT-PCR alone (n = 9), clinically defined criteria including RT-PCR-negative cases (n = 8, 7 of which used Chinese government-issued COVID-19 guidelines to define cases), one using undefined clinical criteria, and one study that did not report how COVID-19 cases were defined.

Forty-three studies evaluated only one test, five compared two tests, three compared 3 tests, one 5 tests, one 9 and one 10 tests. In total the 54 studies reported on a total of 89 test evaluations.

There were 52 evaluations of laboratory-based methods (27 ELISA, 19 CLIA, 6 other methods), including 32 using commercially available laboratory-based kits produced by 11 di erent commercial companies (16 ELISAs, 15 CLIAs and 1 IIFT), two where the manufacturer name was withheld, and 20 classified as using inhouse methods (11 ELISA, 4 CLIA and 5 other approaches).

There were 34 evaluations of lateral flow assays, 23 were described as or discovered to be CGIA, two were FIAs and nine were not described. Thirty-one of the 34 evaluations used commercially available lateral flow assays and three were in-house (including two CGIA and one FIA). Of the 34 evaluations, only three used whole blood (two using the Vivadiag test), and only two used the assays as point-of-care tests rather than in a laboratory setting.

We report the overall methodological quality assessed using the QUADAS-2 tool for all included studies (n = 54) in Figure 2 (Whiting 2011). See Appendix 10 for study-level ratings by quality.

Overall, we judged risk of bias to be high in 48 (89%) studies concerning how participants were selected, 14 (26%) studies related to application of the index test, 17 (31%) through concerns about the reference standard and 29 (54%) for issues related to participant flow and timing. No study had low risk in all domains. We judged that there were high concerns about the applicability of the evidence related to participants in 44 (81%) studies, 17 (31%) related to the index test and 32 (59%) related to the reference standard. Explanations of how we have reached these judgements are given below and in the Characteristics of included studies table.

For participant selection, we judged only one study to be at low risk of bias and five to be of unclear risk. The remaining 48 (89%) we judged to be at high risk of bias (n = 44) either due to the use of a multi-group design with healthy or other disease controls (n = 26) or recruitment of only COVID-19 cases (n = 19), inappropriate exclusions (n = 2) or inappropriate inclusions (n = 15). Numbers per group are not mutually exclusive. Eleven studies (20%) reported consecutive or random recruitment of participants.

We had high concerns about the applicability of the selection of participants in 44 studies (81%) meaning that the participants who were recruited were unlikely to be similar to those in whom the test would be used in clinical practice. This was largely because studies only recruited hospitalised, confirmed cases of COVID-19, o en with severe symptoms (18 studies) or recruited healthy or other disease non-COVID-19 groups (26 studies). We judged 10 (19%) studies likely to have selected an appropriate patient group, including the six studies that recruited participants suspected of COVID-19 prior to definitive testing and four multi-group studies that separately recruited COVID-19 cases and suspected COVID-19 control groups.

Eight studies explicitly reported that they had undertaken the index test with knowledge of whether individuals did or did not have COVID-19, and eight studies determined the threshold to define test positivity by analysing the data, rather than it being predetermined. In 37 studies, reporting of one or both of these issues was too unclear to be able to rule out the possibility of bias. These issues led to the index test performance in 14 studies being rated as at high risk of bias. We judged only three studies to have implemented the index test in a way that protected against the risk of bias.

In 34 studies (63%) we judged the test to be implemented as it would be in practice. Twenty-two of these were evaluations of laboratory-based, commercially available tests, and 12 were evaluations of lateral flow assays associated with commercial test manufacturers, primarily evaluated in an inpatient setting. Two of the 12 evaluated the assays as point-of-care tests in an emergency Cochrane Database of Systematic Reviews room setting. Sixteen studies raised concerns that the tests could not be purchased (high concerns for applicability). The remaining four studies provided inadequate information to make a judgement due to withholding of the names of the commercial tests (one additional study also withheld the names of the lateral flow assays evaluated but scored high concerns as it also reported results for an in-house ELISA test).

We judged 13 studies (24%) to have used an appropriate reference standard and implemented it in ways that prevented bias. In six studies there was a risk of misclassification, as they had used a single, negative RT-PCR result to define the absence of disease in people with suspected COVID-19; eight studies did not report any RT-PCR testing to confirm COVID-19 status for contemporaneous healthy or other disease non-COVID-19 groups; and one study used serology results in part to determine the reference standard diagnosis, thus risking incorporation bias. We judged 24 studies as having unclear risk of bias due to lack of information about blinding of the reference standard to the index test (19/24) or unclear descriptions of the reference standards used (6/24).

We judged the reference standard to be equivalent to WHO or China CDC definitions of COVID-19 in 15 studies (28%). We judged studies that used a definition based only on RT-PCR-positive results as high concern (32 (59%) of studies), and seven studies reported inadequate detail to assess the reference standard.

Twenty-nine (54%) studies were at high risk of bias due to using di erent reference standards to verify COVID-19 and non-COVID-19 cases (n = 19), participants being excluded from the analysis (n = 15), or the inclusion of multiple samples per participant (n = 7). In 20 (37%) studies we could not make judgements on one or more of these issues, primarily due to lack of clarity around participant inclusion and exclusion from analyses. Five studies reported adequate detail to rule out these risks of bias. None of the included studies reported a Standards of Reporting Diagnostic Accuracy Studies (STARD)-style participant flow diagram (Bossuyt 2015) , and none mentioned that they aimed to report in line with STARD reporting recommendations for test accuracy studies.

In 39 studies all authors declared no conflicts of interest although four included co-authors a iliated to test manufacturers. Ten studies did not provide a conflict of interest statement (two of these included co-authors a iliated to test manufacturers or biotechnology companies); and in the five remaining studies at least one author declared conflicts of interest in relation to test manufacturers (four studies) or vaccine companies (one study).

Nine studies provided no funding statement, six reported no funding sources to declare, and 39 studies reported one or more funding sources. The reported funding sources were primarily public funding sources. Two studies reported receipt of equipment 'in kind' from test manufacturers and two studies reported private donors.

We included 54 di erent studies, which were reported in 57 publications. Fourteen of the 54 studies evaluated more than one test (Table 1) 

We are unable to distinguish between studies that evaluated the accuracy of antibody tests to identify current infection from past infection. Whilst time since onset of symptoms is strongly related to whether an infection was current or past, few studies reported whether participants' symptoms had resolved (and thus they were in a convalescent state) when serology samples were taken. Whilst 21 days post-symptom onset is assumed to be a point where COVID-19 cases are likely to be convalescent, many participants in these studies were hospitalised for prolonged periods and likely to reflect those with more severe and long-lasting symptoms.

A key aspect of interpreting the sensitivity of the tests is the relationship between accuracy and days since onset of symptoms. Sixteen (30%) studies only presented results aggregated over 0 to more than 35 days since onset, and did not present data (or provide datasets) that disaggregated data by week. The figures in Appendix 11 show forest plots of sensitivity and specificity estimates including these studies for IgG, IgM, and IgG/IgM (either positive), which clearly depict substantial heterogeneity in sensitivity, with estimates ranging from 0% to 100% for all three markers. Forest plots of results for IgA, total antibodies, IgA/IgG, IgA/IgM (Appendix 11), show similar heterogeneity with smaller numbers of studies. Given the heterogeneity and the known strong relationship of sensitivity with time, computation of an average estimate of sensitivity from these studies would be misleading and serves no purpose. Figure 3 present the results disaggregated by week of testing since onset of symptoms for IgG (from 23 studies), IgA (from 4 studies), IgM (from 24 studies), total antibodies (from 5 studies), combination of IgG/IgM (from 21 studies), and IgA/ IgG (from 1 study; these results are based on a maximum of 12 participants per time period and we will not comment on them further). We did not find any data disaggregated by week for IgA/ IgM. Forest plots of these data are given in Figure 4 , Figure 5 and Figure 6 . We have undertaken meta-analyses of data stratified by week as heterogeneity, whilst still present, is substantially less. As indicated in Table 2 , the strength of the relationship of time with sensitivity shows exceptionally high levels of statistical significance (P < 0.0005). All further analyses of sensitivity in this report are thus stratified by week since symptom onset.

The numbers of individuals contributing data within each study within each week are very small, thus by pooling these data across studies these meta-analyses contribute clarity to the relationship between sensitivity and time, although the important limitations of these studies as described above should be considered when interpreting all findings. Table 2 .

It is important to note that these estimates are based on pooling multiple cross-sectional studies, and are not based on tracking the same groups of participants over time or even using the same tests. The reasons why individuals are included at some particular time points and not at others is mostly not reported.

Estimates of sensitivity beyond three weeks are based on smaller sample sizes, with a maximum of 12 studies contributing data in weeks 4 and 5, and only four studies providing any follow-up information beyond week 5. Estimates for IgA and total antibodies are based on fewer than 100 samples/participants and we will not comment upon them further. 

We estimated antibody test specificity from 35 studies. Specificity estimates for all studies are presented in Appendix 11 for IgG, IgM, IgG/IgM, IgA, total antibodies, and IgA/IgG. Results pooled across all studies are in Table 3 and show specificity exceeding 98% for all antibody types, with precise estimates (confidence intervals up to 2 percentage points wide), particularly for IgG, IgM, total antibodies and IgG/IgM, where estimates are based on several thousand non-COVID samples. Inspection of the figures shows low heterogeneity in study estimates of specificity across studies. Nine studies provided some information on the cross-reactivity of other infections, including other coronaviruses, with the SARS-CoV-2 antigens used in the assays (Table 4) .

The majority of studies only included participants who were diagnosed with COVID-19 based upon observing a positive RT-PCR test. However, in clinical practice it is common to encounter patients from whom positive RT-PCR results are never obtained, but who demonstrate clinical and imaging features of COVID-19. Diagnostic criteria for COVID-19 produced by WHO and the China CDC include definitions for suspected COVID-19 in RT-PCRnegative patients. Twelve studies defined the presence of COVID-19 using these criteria, thus including RT-PCR-negative patients in the COVID-19 group as well as RT-PCR-positive patients. We compared estimates of sensitivity between studies using a RT-PCR-positive reference standard definition with a criteria-based reference standard (including both RT-PCR-positives and RT-PCRnegatives; Table 5 ). We stratified the analysis for weeks since onset of symptoms. All the observed di erences were within magnitudes expected by chance.

In a further analysis, we separated COVID-19 participants who were RT-PCR-positive from those who were RT-PCR-negative, where studies allowed, and subgrouped the results to investigate whether there is a di erence in accuracy according to RT-PCR status. Data from only three studies could be included in this analysis ( Figure  7 ; Figure 8 ; Figure 9 ). Di erences in estimates of sensitivity (pooled stratifying for weeks since onset of symptoms), varied in direction Cochrane Database of Systematic Reviews Figure 9 . Sensitivity of IgG/IgM in PCR+ve and PCR-ve COVID-19 cases by week since onset of symptoms.

We classified the reference standard used to verify non-COVID cases into three main groups: pre-pandemic controls (both healthy and with other diseases) who underwent no RT-PCR testing, current controls from healthy or other disease groups (typically who also did not undergo RT-PCR testing), and individuals who were investigated for COVID-19 but deemed non-COVID cases. Whilst results were similar for IgG and IgM, we noted more false positives for the IgG/IgM outcome in the studies using a COVID suspect group than in other studies (Table 3) .

We further investigated the heterogeneity in sensitivity estimates at any time point according to test technology type. We considered di erences between CGIA, CLIAs, ELISAs and tests we can only describe as lateral flow assays due to lack of any names or detail Cochrane Database of Systematic Reviews (this group originate from the UK National COVID Testing Scientific Advisory Panel, which withheld names of the tests evaluated due to confidentiality clauses in the legal contracts with the manufacturers Adams 2020 [A] ). There were inadequate numbers of studies evaluating FIAs and indirect immunofluorescence tests, luciferase immunoprecipitation assays and 'S-flow' assays to analyse, and we were only able to assess IgG, IgM and IgG/IgM targets. In a sensitivity analysis we restricted the included studies to those that used commercial (rather than in-house) tests.

We obtained estimates from a model that included all data stratified by weeks since onset of symptoms. The results presented in Table 7 and below correspond to estimates from the model of performance in week 3 post-symptom onset.

For IgG, there were clear di erences in the sensitivity of assays, with CLIA (94.6%), CGIA (87.3%) and ELISA (85.8%) all outperforming the unknown lateral flow assay tests (76.0%). The di erences between the groups was beyond that expected by chance (P = 0.004), but largely driven by the low value for lateral flow tests (all of the data coming from 40 COVID-19 patients in the UK National COVID Testing Scientific Advisory Panel study tested multiple times).

For IgM, although laboratory-based ELISA (84.5%) and CLIA (80.9%) outranked lateral flow CGIA (69.5%) and the unknown lateral flow assays (51.4%), the di erences observed were in the realms of those expected by chance (P = 0.11).

In the smaller subset of studies that evaluated tests combining IgM/ IgG, the performance of laboratory CLIA tests (97.3%) ranked above those of CGIA (91.4%), ELISA (90.5%) and unknown lateral flow tests (85.8%). These di erences were beyond those expected by chance (P = 0.01)

Excluding the in-house tests, and thus restricting the analysis to only commercial tests, made little di erence to estimates of sensitivity.

Analyses of specificity presented by assay type are also given in Table 7 . Di erences in specificity of IgG and IgM between assay types were small, CLIA and CGIA tests showed lower specificity for IgG/IgM tests than ELISA and LFIA, but confidence intervals on all estimates are wide.

We have tabulated the results by brand for the 27 commercial tests: 15 tests for IgG Table 8; 14 tests for IgM Table 9 ; and nine tests for IgG/IgM Table 10 . The study data for these estimates are provided in Figure 4 , Figure 5 and Figure 6 . Appendix 12 tabulates the information that we have been able to derive regarding the current availability of these commercially produced tests. Data for sensitivity are stratified by week of onset of symptoms and we present the numbers of studies and samples from which data are available for each time interval. Caution is required in the interpretation of these data as many are based only on single studies with small sample sizes. We present confidence intervals to quantify the uncertainty in the estimates. We would advise focusing on estimates based on at least 100 samples/participants per week further. Three tests have estimates of sensitivity based on more than 100 samples (Beijing Wantai ELISA, Bioscience Co. (Chongqing) CLIA, Zuhai Livzon ELISA). We evaluated the studies that we pooled to create these estimates as having multiple domains at risk of bias and having concerns about the applicability of the findings (all studies having at most 2 of the 7 ratings in the QUADAS-2 assessment described as low risk or low concern). Eight tests have estimates of specificity based on more than 100 samples, with estimates over 98% for five tests (Bejing Hotgen ELISA, Beijing Wantai ELISA, Beijing Wantai CGIA, Xiamen InnodDx Biotech ELISA, Zhuhai Livzon ELISA). Again please note the concerns in the risk of bias and applicability of these findings.

Our protocol included additional planned analyses by:

• current infection or past infection;

• study design; and • setting.

We could not investigate these sources because of lack of variability across the studies in these features. Only two studies explicitly stated that they recruited only convalescent patients, and 48 (85%) studies recruited hospital inpatients. For study design only five out of 54 (11%) studies recruited a single group of suspected COVID-19 patients, and did not use a 'COVID-19 cases only' study, or a 'twogroup' study design.

We observed direct evidence of selective reporting through the withholding of names of the nine lateral flow assay testing brands from the UK National COVID Testing Scientific Advisory Panel study (Adams 2020 [A] ). The paper states, "Individual manufacturers did not approve release of device-level data, so device names are anonymised" (Adams 2020 [A] ). The sensitivity estimates for the lateral flow assays in this study (which are most likely to be CGIA) were noted to be lower than estimates for CGIA tests from other studies. Four other studies also did not identify the test that they were evaluating.

This is the first version of a Cochrane living review summarising the accuracy of antibody tests for detecting current or previous SARS-CoV-2infection. This version of the review is based on published studies or studies available as preprints up until the 27 April 2020. The speed of development and publication of studies for COVID-19 antibody tests is unprecedented, and the content of this review will always be out of date. We are continuously identifying new published studies, and plan to update this review several times during the next few months. Cochrane Database of Systematic Reviews used in clinical care will be lower than that observed here. We did locate six evaluations recruiting patients identified in clinical pathways before it was established whether they had COVID-19. This is more likely to produce results that reflect clinical practice, and we encourage future evaluations to consider this study design.

A concern with this review, and with its updates, is the high likelihood of selective reporting of results, particularly by manufacturers. We have already noted manufacturers being unwilling to be identified in the UK National COVID Testing Scientific Advisory Panel study (Adams 2020 [A] ). Unlike randomised controlled trials of interventions, there are no requirements for test accuracy studies to be prospectively registered on study registers, nor to publish their findings. Many industry studies are only briefly described on 'Information for use' documents included with the tests, and study reports submitted to regulators are regarded as confidential. We are also aware that there are independent studies undertaken by National Public Health bodies, some of which have been submitted to FIND's data tracking tool for speedy data sharing. We plead for greater transparency and full publication in this field and continue to encourage laboratories to submit data and reports via FIND's portal. We request sharing of any unpublished reports for inclusion in future updates (please send to coviddta@contacts.bham.ac.uk). We have contacted test manufacturers to request full study reports which we will include in a future update of this review.

We summarise 10 key findings from this review.

1. Evaluations of most antibody tests on the market are not available as publications or even as preprints. This review has evaluated data from 25 commercial tests and numerous inhouse assays. These represent a small fraction of the antibody assays currently available. We have identified 66 additional studies of antibody tests published or available as preprints up until 25 May 2020, which we will appraise for inclusion in the review update, but there still remain no published data for the majority of tests on the current FIND list. 2. The design and execution of the current studies limits the strength of conclusions that we are currently able to draw. Nearly all studies sampled COVID-19 cases and non-COVID cases separately, and methods for selecting participants were not described. Only four studies reported blinding reference standard and index tests, and some reference standards may misclassify individuals. 3. Many studies only applied tests in laboratory settings on plasma or serum, whilst they are also approved for use as point-of-care tests using whole blood. From these data it is not possible to ascertain the clinical accuracy of these tests in lower resource and more accessible settings. 4. Sensitivity varies with the time since of onset of symptoms.

Figures from the studies showed the ability of antibody tests to detect SARS-CoV-2infection is very low in the first week (average sensitivity 30.1%, 95% CI 21.4 to 40.7) and only moderate (average sensitivity 72.2%, 95% CI 63.5 to 79.5) in the second week post-symptom onset. These estimates are based on patients who have been hospitalised with COVID-19, and remain in hospital at the time of sampling, and thus are likely to represent the more severe end of the disease spectrum and are potentially individuals with higher antibody responses. 

Our review used a broad search screening all articles concerning COVID-19. We undertook all screening and eligibility assessments, QUADAS-2 assessments (Whiting 2011), and data extraction of study findings independently and in duplicate. Whilst we thus have reasonable confidence in the completeness and accuracy of the findings up until the search date, should errors be noted please inform us at coviddta@contacts.bham.ac.uk so that we can check and correct in our next update.

Weaknesses of the review primarily reflect the weaknesses in the primary studies and their reporting. Many studies omitted descriptions of sample recruitment, and key aspects of study design and execution. Some studies omit information that allows the tests to be identified. We have had to treat studies that describe their data as being based on 'samples' as if the samples were individual patients. We have been explicit about these issues where they arose.

More than half (28/54) of the studies we have included are currently only available as preprints, and as yet, have not undergone peer review. As published versions of these studies are identified in the future, we will double-check study descriptions, methods and findings, and update the review as required.

We also did not make within-study comparisons between tests. Two studies (Adams 2020 [A] ; Lassauniere 2020 [A] ), evaluated panels of nine or 10 tests, nine other studies evaluated two, three, or five tests. As we could not identify tests in Adams 2020 [A] , and the sample of Lassauniere 2020 [A] was very small, it is not possible from the studies available at this time to make direct comparisons between alternative tests.

We identified only one study that included comparison of test results with a reference standard of a neutralisation assay in studies identified for inclusion in this first version of the review (Thompson 2020), but we did not include these data in this version of the review. We are aware of several more studies of these assays in more recent publications and will include this as a new target condition in the next update of the review.

In such a current and fast moving field searches will always be out of date. However we are committed to ongoing updates of this living review

In the background we outlined four main roles for antibody testing that would be addressed in this review.

1. In diagnosis of infection in patients presenting with symptoms of suspected COVID-19, particularly where molecular testing had failed to detect the virus. Most studies included in the review collected data from patients in the acute phase of disease in hospital settings and thus provide evidence to address this question amongst hospitalised patients. The review showed that antibody tests had very low sensitivity in the first week following onset of symptoms, but sensitivity rose in the second week, and only exceeded 90% in the third week. In addition we saw no di erence in sensitivity of tests according to RT-PCR status. We had no data to inform the accuracy of the test in primary care and community settings for the purpose of diagnosis, where patients are likely to have milder symptoms. 2. In assessment of immune response in patients with severe disease. We stated in the Background that we would not cover this in this review. In any case, we found no studies that directly addressed this question. Assessment of the accuracy of a test used for assessment of immune response would involve comparison with a reference standard test of antibody response, rather than evidence of infection. 3. To assess whether individuals have had a SARS-CoV-2 infection.

As above, we found no studies that directly addressed this question, and very few studies were undertaken in community settings in patients who had not undergone RT-PCR testing during their symptomatic period. Conclusions about the likely value of tests for this purpose rely on the sensitivity of the tests being no di erent in mild disease than in severe disease that requires hospital admission. 4. In seroprevalence surveys for public health management purposes. We also found no studies that directly addressed this question (although Bendavid 2020 is a seroprevalence study, it did not evaluate the accuracy of the test in the seroprevalence sample). High specificity of tests is essential in seroprevalence testing, which appears likely for many of the tests included in this review. However, the suitability of pre-pandemic samples to establish specificity requires further discussion. We found no di erence in specificity between pre-pandemic and current non-COVID-19 samples, but lower specificity in those where COVID-19 was ruled out a er initially being suspected. This either reflects misclassification, or a true lower specificity in those presenting with symptoms. As sensitivity of the tests was mainly evaluated in hospitalised patients it is also unclear whether the tests have the ability to detect lower antibody levels likely in non-hospitalised COVID-19 patients.

Based on this analysis, in patients presenting with symptoms of acute suspected COVID-19, antibody tests have no role on their own as the primary test to use in the diagnosis of COVID-19 when patients present during the first week since onset of symptoms, as their sensitivity is too low.

A small number of studies showed that the sensitivity of antibody tests is no di erent in those who were reverse transcription polymerase chain reaction (RT-PCR)-negative rather than RT-PCRpositive. Thus in hospitalised patients where molecular tests have failed to detect virus, antibody tests have an increasing likelihood of detecting immune response to the infection as time since onset of symptoms progresses.

There may therefore be a role in using antibody tests in COVID-19 RT-PCR-negative but strongly suspected patients where patients are more than two weeks since the onset of symptoms. This is in line with the most recent version of the China CDC (National Health Commission of the People's Republic of China) COVID-19 case definition (Appendix 2).

The data analysed in the review suggest that antibody tests are likely to have a useful role for detecting previous SARS-CoV-2 infection if used at 15 days or more a er the onset of symptoms. This conclusion needs to be cautioned by the poor study quality, the small sample sizes and restricted number of tests that have undergone evaluation. In addition, we have scant data to inform the accuracy of the test in non-hospitalised patients with milder disease, and too little data to comment on accuracy beyond 35 days.

Using, for illustration the overall IgG/IgM data at days 15 to 21 (sensitivity 91.4%, 95% CI 87.0 to 94.4 and specificity 98.7%, 93% CI 97.2 to 99.4), we have computed predictive values, and the numbers of true positives, false positives, false negatives and true negatives in a sample of 1000, at a prevalence of 50% (a value seen in healthcare worker populations who have su ered respiratory symptoms in the past months). In this scenario, the positive predictive value is estimated as 99% (95% CI 97 to 99), the negative predictive value as 92% (95% CI 88 to 95), and of 1000 people undergoing testing we would anticipate 7 (95% CI 3 to 14) false positives and 43 (95% CI 28 to 65) false negatives.

Please note that it is not certain whether a detectable immune response indicates that a patient is immune nor no longer infectious.

Trusted evidence. Informed decisions. Better health.

The duration of antibody rises is not yet known, and this review contains very little data beyond 35 days post-onset of symptoms.

In the 'Summary of findings' table we present scenarios for the likely numbers of missed cases (false negatives) and false positive cases for prevalences of 2%, 5%, (likely values in national surveys), 10% and 20% (likely values in high-risk settings such as healthcare workers), presuming that the performance of an IgG/IgM test would continue at the same level as for 14-21 days. Again this conclusion needs to be cautioned by the poor study quality, the applicability of the study settings, the small sample sizes and restricted number of tests that have undergone evaluation. At a prevalence of 20%, a possible value in surveys in high-risk settings, 17 (95% CI 11 to 26) would be missed per 1000 people tested and 10 (95% CI 5 to 22) would be falsely positive. At a lower prevalence of 5%, a likely value in national surveys, 4 (95% CI 3 to 7) would be missed per 1000 tested, and 12 (95% CI 6 to 27) would be falsely positive.

Many more high-quality evaluation studies of COVID-19 antibody tests are needed in patients more than 21 days post-symptom onset, and in people in the community, particularly those who experience milder symptoms, or who are asymptomatic (but known to be infected).

Future studies must report data on sensitivity disaggregated by time since onset of symptoms. In future updates of this review we will not include studies for analysis of sensitivity where this has not been done. We would suggest that studies standardise how they define time since symptom onset (not, for example, using time since positive RT-PCR results since this has no biological basis) and present results using standard time groupings (we suggest initially by week up until 35 days and larger time intervals beyond). Studies that sample from the same patients at several time points over time are needed to fully understand how time since symptom onset directly a ects performance -our current estimates are based on collation of multiple cross-sectional studies, which has limitations.

Primary studies need to be undertaken for the many tests that are on the market but as yet have no independent evaluations. Future studies should evaluate test performance in consecutive individuals who are recruited in clinical care with suspected COVID-19, to estimate both sensitivity and specificity, as this will estimate the likely performance of the tests in practice.

COVID-19-positive cases who are RT-PCR-negative should be included as well as those confirmed RT-PCR, in accordance with the World Health Organization (WHO) and China CDC case definitions.

Studies should ensure that the test is used as it is intended to be used in clinical practice (i.e. being undertaken at point-ofcare rather than in laboratories (where appropriate) on the right specimens, by the intended healthcare worker). However, when validating people with suspected COVID-19 who do not have a positive identification of COVID-19 by RT-PCR, these studies need to take care to confirm or rule out COVID-19 by obtaining standardised evidence from other sources (e.g. repeat RT-PCR, CT scans, followup). Future studies need to recruit larger sample sizes and consider recruiting from multiple centres. We did not find any multicentre studies for this review.

We would also encourage investigators to utilise blinding in their study designs, such that index tests are undertaken without knowledge of the reference standard diagnosis, and likewise, reference standards are determined without knowledge of the index test findings.

We need good data upon which to compare tests. The strongest comparisons are made by testing the same participants multiple times with di erent tests. Whilst it is possible for this to be undertaken in prospective studies, it is easier to undertake in laboratory-based studies utilising serum banks, which will compromise on the applicability of the absolute estimates of test accuracy, but provide some information about comparability.

From these studies we can only draw limited conclusions about cross-reactivity of COVID-19 tests with other coronaviruses as these data are summarised in analytical accuracy studies. It would be of value for these results to be reviewed as well as clinical accuracy studies.

Study reporting requires substantial improvement. The STARD checklist outlines standard requirements for the reporting of a test accuracy study, which study investigators should take note of when planning their study to ensure the relevant information is collected and reported. No study was found that reported data using a STARD participant flow-diagram (Bossuyt 2015).

Due to the speed of new publications in this field, frequent updates of this review are required. Future updates will not include data on tests that are not (or not likely to become) commercially available (thus we will exclude all in-house assays).

Members of the Cochrane COVID-19 Diagnostic Test Accuracy Review Group include:

• the project team (Deeks JJ, Dinnes J, Takwoingi Y, Davenport 

Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Annals of Internal Medicine (in press).

Veritas Health Innovation Covidence. Version accessed 27 April 2020. Melbourne, Australia: Veritas Health Innovation.Available at covidence.org.

Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Cochrane Database of Systematic Reviews High risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Adams 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Adams 2020 [A] )

Index tests Adams 2020 [B] is test [B] from the following entry: 

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Adams 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Adams 2020 [A] )

Index tests Adams 2020 [C] is test [C] from the following entry: 

Index tests Adams 2020 [D] is test [D] from the following entry: See main entry for this study for characteristics and QUADAS-2 assessment (Adams 2020 [A] )

Index tests Adams 2020 [G] is test [G] from the following entry: 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

No If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test Unclear Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Bendavid 2020 (Continued) 

If a threshold was used, was it pre-specified? No

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Index tests This entry (Burbelo 2020 [B] ) refers to the LIPS assay to detect antibodies to the spike (S) protein; see (Burbelo 2020 [A] for further study characteristics and QUADAS-2 assessments) 

If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes

High risk

Patient Sampling The report contains 3 different groups that fit with 2 different comparisons.

Cassaniti 2020 (A) 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition? 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Yes If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question? 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Unclear Du 2020 (Continued) Cochrane Database of Systematic Reviews

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Unclear

Could the conduct or interpretation of the index test have introduced bias?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Visible line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result. Blinded to reference standard: NR Threshold predefined: [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Positive results showed the appearance of both control line and testing line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result.

Target condition and reference standard(s) Low concern DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis?

Unclear Did all participants receive a reference standard?

Were results presented per patient? No

High risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Gao 2020b [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Gao 2020b [A] )

Index tests Gao 2020b [B] is test [B] from the following entry:

Antibody tests for identification of current and past infection with SARS-CoV-2 [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Visible line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result. Blinded to reference standard: NR Threshold predefined: [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Positive results showed the appearance of both control line and testing line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result. Index tests Gao 2020b [C] is test [C] from the following entry:

Test name: [A] CLIA; [B] GICA; [C] [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Visible line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result. Blinded to reference standard: NR Threshold predefined: [A] samples with an concentration ≥ 8 arbitrary unit (AU)/mL were considered positive. [B] Positive results showed the appearance of both control line and testing line. [C] The absorbance at 450 nm (A450 nm) of each well was determined and the cut-o value was 0.10+Anegative control. A value > cut-o value was considered a positive result. Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests? 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test Unclear

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? 

Were results presented per patient? No

High risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Grzelak 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Grzelak 2020 [A] )

Index tests This entry (Grzelak 2020 [B] ) refers to test [B] in the list below; see Grzelak 2020 [A] for further study characteristics and QUADAS-2 assessments) 5 tests evaluated: A. LIPS (S1 protein) 

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Grzelak 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Grzelak 2020 [A] )

Index tests This entry (Grzelak 2020 [C] ) refers to test [C] in the list below; see Grzelak 2020 [A] for further study characteristics and QUADAS-2 assessments) 5 tests evaluated:

Antibody tests for identification of current and past infection with SARS-CoV-2 

See main entry for this study for characteristics and QUADAS-2 assessment (Grzelak 2020 [A] )

This entry (Grzelak 2020 [D] ) refers to test [D] in the list below; see Grzelak 2020 [A] for further study characteristics and QUADAS-2 assessments) 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? 

High risk

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test Unclear

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing 

High risk

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

DOMAIN 3: Reference Standard 

Patient Sampling Single-group study estimating sensitivity for detection of active or recent infection in people with suspected COVID-19. Patients with highly suspected COVID-19 (n = 57; 24 PCR-positive) defined by exposure history, one of:

1. the patient has a history of travel or resident in Wuhan or surrounding area, or communities with COVID-19 patients within 14 days before onset; 2. has a contact history with people infected with COVID-19 (positive NAAT) within 14 days before onset; 3. has a contact history with patients from Wuhan and surrounding areas, or has a contact history with patients who have fever or respiratory symptoms from communities with COVID-19; 4. cluster onset; and by clinical manifestations, 2 of: 1. fever and (or) respiratory symptoms; 2. conforming to the imaging features; 

High risk 

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes 

Could the patient flow have introduced bias?

Jia 2020 (Continued) 

High risk

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

DOMAIN 3: Reference Standard Jin 2020 (Continued) 

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Did all participants receive a reference standard?

Were results presented per patient? Yes

High risk

Patient Sampling 2-group design estimating sensitivity and specificity for 9 tests Groups: [1] COVID-19-positive group (n = 30) admitted to ICU; [2] non-COVID-19 group (n = 82) including pre-pandemic (2017) blood donors (n = 10); acute viral respiratory tract infections with other coronaviruses (n = 5) or non-coronaviruses (n = 45); dengue virus (n = 9), CMV; n = 2 and Epstein Barr virus (n = 10 

Exposure history: NR Index tests 9 tests evaluated, 3 ELISA and 6 LFIA; this entry (Lassauniere 2020 [A] ), refers to test [A] in the list below: [A] Cochrane Database of Systematic Reviews differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis?

No Did all participants receive a reference standard?

Were results presented per patient?

High risk 

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing [A] ) refers to test [A] in the list below Test name: [A] not named; [B] commercial ELISA kit Manufacturer: [A] in-house; [B] Darui Biotech, China Ab targets: [A] and [B] : IgM, IgG Antigens used: [A] 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? No

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? 

Were results presented per patient? Yes

High risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Lin 2020a [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Lin 2020a [A] )

Index tests 2 tests were evaluated; this entry (Lin 2020a [B] ) refers to test [B] in the list below Test name: [A] not named (CLIA); [B] commercial ELISA kit Manufacturer: [A] in-house; [B] Darui Biotech, China Ab targets: [A] and [B] : IgM, IgG Antigens used: [A] 

Patient Sampling 1-group study recruiting patients estimating sensitivity and specificity 

High risk

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Unclear risk Were results presented per patient? Yes

Low risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Lippi 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Lippi 2020 [A] )

Index tests 2 tests were evaluated; this entry (Lippi 2020 [B] ) refers to test [B] in the list below Test name: [A] MAGLUMI 2019-nCoV IgG and IgM (2 indirect tests) [B] Anti-SARS-CoV-2 IgA and IgG ELISA Manufacturer: [A] SNIBE -Shenzhen New Industries Biomedical Engineering Co., Ltd, Shenzhen, China [B] Euroimmun AG, Lübeck, Germany Ab targets: [A] IgM or IgG ; [B] IgA or IgG Antigens used: [A] CoV-S (spike) and e CoV-N (nucleocapsid); [B] 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question? 

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes

High risk 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard? Yes 

High risk

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? 

Patient Sampling Single-group study to estimate sensitivity and specificity for detection of active or prior infection Cohort of close contacts (n = 164, 23 cases) of 2 index cases (diagnosis confirmed 4 February 2020; contacts between 20 January-6 February 2020 identified and PCR tested) Additional cohorts reported but not extracted included: a. follow-up cohort in RT-PCR-positive confirmed cases sampling every 3 days (n = 63 subset of cross-sectional study); does not provide accuracy data b. cohort of RT-PCR-negative suspects (n = 52); did not provide full accuracy data (specificity only could be extracted) 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

No Did all patients receive the same reference standard? Yes

Did all participants receive a reference standard? Yes

Were results presented per patient? Yes 

Low risk

Patient Sampling Single-group study to estimate sensitivity for diagnosing acute phase infection RT-PCR-positive confirmed cases (n = 285). No further detail of inclusion or exclusion criteria. Additional cohorts reported but not extracted included: a. follow-up cohort in RT-PCR-positive confirmed cases sampling every 3 days (n = 63 subset of cross-sectional study); does not provide accuracy data b. cohort of RT-PCR-negative suspects (n = 52); did not provide full accuracy data (specificity only could be extracted) c. cohort of asymptomatic contacts of 2 confirmed cases extracted as Long 2020 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? Dates: 19 January-9 February 2020 Symptoms and severity: n = 26. Critical case = any one of a) ARDS or oxygen saturation < 93% and needing mechanical ventilation invasively or non-invasively; b) shock; c) complication of organ failure requiring ICU support N= 54 non-critical case (not meeting criteria a) or b) or c) above Sex: 38.7% female Age: 55 years (IQR 45-64) Exposure history: for 45/80: incubation period (defined as interval between earliest date of SARS-Cov-2 exposure (unambiguous close contact with confirmed COVID-19 case) and earliest date of symptom onset) range 0-23 days, median 5 (IQR 2-10)

Index tests 3 tests evaluated, this entry (Lou 2020 [A] ) refers to test [A] Test name: [A] ELISA; [B] CGIA; [C] 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Trusted evidence. Informed decisions. Better health.

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? No Did all participants receive a reference standard?

Were results presented per patient? Yes Library Trusted evidence. Informed decisions. Better health.

Index tests 3 tests evaluated, this entry (Lou 2020 [B] ) refers to test [B] Test name: [A] ELISA; [B] CGIA; [C] 

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Lou 2020 [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Lou 2020 [A] )

Index tests 3 tests evaluated, this entry (Lou 2020 [C] ) refers to test [C] Test name: [A] ELISA; [B] CGIA; [C] 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? No

High risk 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Yes Did all participants receive a reference standard?

Were results presented per patient? No

High risk

Patient Sampling 2-group design estimating sensitivity and specificity in acute disease [1] SARS-CoV-2 cases confirmed by RT-PCR (n = 9, 31 samples)

[2] Healthy blood donors (n = 45) date NR Recruitment method and exclusion criteria NR Third group of RT-PCR confirmed cases from France (n = 3, 10 samples excluded by review author team)

Patient characteristics and setting [1] Inpatient (plus initial testing prior to admission) at hospital in Munich, Germany. Cases are epidemiologically linked, identified through exposure to known cases, and occurred after 23 January 2020, discovered on 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? Were the index test results interpreted without knowledge of the results of the reference standard?

No If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? Target condition and reference standard(s) 1. RT-PCR following WHO guidelines for qRT-PCR, using throat swabs (Chinese CDC recommended kit used, BioGerm, Shanghai, China) 2. clinically diagnosed as SARS-CoV-2 infection according to the 5th edition of guideline on diagnosis and treatment of the novel coronavirus pneumonia. Specifically, the clinical diagnosis means the suspected cases were negative to the real-time RT-PCR test but presented viral pneumonia by radiography Samples taken during inpatient stay but no details about timing or personnel for test interpretation Flow and timing All participants received a reference standard, but there was differential verification with some patients confirmed by RT-PCR and others RT-PCR-negative but confirmed by radiography. Subset who were RT-PCR-positive are reported separately. 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes Library Trusted evidence. Informed decisions. Better health.

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis? No Did all participants receive a reference standard? Yes

Were results presented per patient? Yes

High risk

Patient Sampling 4-group study recruiting patients estimating sensitivity and specificity

[1] Confirmed COVID-19 cases (RT-PCR-positive) (n = 503) and

[2] suspected COVID-19 cases based on epidemiological history, clinical symptoms and chest X-ray but 3 x PCR-negative (n = 52)

Apparently contemporaneous controls, including:

[3] hospitalised with non-COVID-19 conditions (PCR testing not described) (n = 972)

[4] healthy controls (n = 586)

Trusted evidence. Informed decisions. Better health.

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing Cochrane Database of Systematic Reviews

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? No Did all participants receive a reference standard?

Were results presented per patient? Unclear

High risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (To 2020a [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (To 2020a [A] )

Index tests 2 tests evaluated, this entry (To 2020a [B] ) refers to test [B] 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question? Cochrane Database of Systematic Reviews

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis? Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes

Unclear risk

Patient Sampling See main entry for this study for characteristics and QUADAS-2 assessment (Wang 2020a [A] )

See main entry for this study for characteristics and QUADAS-2 assessment (Wang 2020a [A] )

Index tests 2 tests evaluated, this entry( Wang 2020a [B] ) refers to test [B] A. SARS-CoV-2 IgM detection kit CGIA (Beijing Hotgen Biotechnology Co., Beijing, China) (POC test, evaluation appears to be laboratory-based) 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Low concern DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Unclear Did all patients receive the same reference standard?

Were all patients included in the analysis?

Unclear Did all participants receive a reference standard?

Were results presented per patient? Yes

Unclear risk

Patient Sampling Single-group study to estimate sensitivity for diagnosing active or prior infection 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Xie 2020a (Continued) 

Are there concerns that the included patients and setting do not match the review question?

High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? Were the index test results interpreted without knowledge of the results of the reference standard?

Unclear If a threshold was used, was it pre-specified? Unclear

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test No

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it pre-specified? Yes

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

The reference standard does not incorporate the index test

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard? 

Presented below are all the data for all of the tests entered into the review. In-house, S-based ELISA 1 (1%)

In-house, S-based LIPS 1 (1%)

In-house, rN-based ELISA 1 (1%)

In-house, rS-based ELISA 1 (1%)

In-house CGIA 2 (2%)

In-house CLIA 5 (6%)

In-house ELISA 6 (7%)

In-house FIA 1 (1%)

In-house S-flow 1 (1%)

In-house -N-based ELISA 1 (1%)

In-house -N-based LIPS 2 (2%)

In-house -S1-based LIPS 1 (1%)

In-house -tri-S-based ELISA 1 (1%)

In-house Anti-SARS-Cov ELISA 1 (1%) Table 3 . Specificity and impact of reference standard for non-COVID cases (Continued) a Includes studies that are categorised as mixed/other not included in the subgroups. b Confidence intervals computed using binomial exact on totals.

Cai 2020

In-house CLIA Reported no cross-reactivity in 167 sera from patients with infection with other pathogens (influenza A virus (25), respiratory syncytial virus (7), parainfluenza virus (8) (22), syphilis (23) and saccharomycopsis (3)).

In-house ELISA Reported cross-reactivity to SARS-CoV-2 spike protein in sera from patients with SARS-1 and MERS-CoV, and no cross-reactivity with NL63, OC43, HKU1, 229E

In-house ELISA Reported Western Blot cross-reactivity analysis in plasma samples positive for human CoV-229E, -NL63, -OC43, -HKU1, and SARS-CoV. Strong cross-reactivity was observed only for SARS-CoV.

Infantino 2020 Shenzhen YHLO CLIA Observed no cross-reactivity in sample from blood donors from the COVID-19 era (winter 2019) but positive results in two samples from people with CMV infections and 2 with rheumatic disease.

Lassauniere 2020 [A] [A] Beijing Wantai ELISA Included sera from patients with acute viral respiratory tract infections caused by other coronaviruses (n = 5) or non-coronaviruses (n = 45), and sera from patients positive for dengue virus (n = 9), CMV (n = 2) and Epstein Barr virus (n Test for difference in sensitivity between RT-PCR-positive and RT-PCR-negative group: P = 0.90 Cochrane Database of Systematic Reviews CI: confidence interval; RT-PCR: reverse transcription polymerase chain reaction Table 6 . Studies reporting sensitivity in both RT-PCR-positive and RT-PCR-negative subgroups (Continued) a The sensitivity estimates are produced from a model that combines all data from both subgroups and time-groups, stratifying by timegroup. The estimate corresponds to sensitivity in Days 15-21. b RT-PCR-positive data have only been included here when the study includes a RT-PCR-negative subgroup as well. 

In areas with no known COVID-19 virus circulation confirmation requires:

• NAAT positive for at least two different targets on the COVID-19 virus genome, of which at least one target is preferably specific for COVID-19 virus (or SARS-like coronavirus) using a validated assay; OR • NAAT-positive result for betacoronavirus, and COVID-19 virus identified by sequencing partial/whole genome of virus (sequence target larger or different from the amplicon probed in the NAAT assay).

Discordant results should be resampled. In areas where COVID-19 virus is widely spread a simpler algorithm might be adopted (e.g. RT-PCR of a single discriminatory target)

talisation and an absence of alternative explanation.

virus is inconclusive. OR A suspect case for whom testing could not be performed for any reason.

could support diagnosis once validated serology tests are available.

Serological assays will play an important role in research and surveillance but are not currently recommended for case detection.

NAAT: nucleic acids amplification test; RT-PCR: reverse transcription polymerase chain reaction; Source: WHO 2020. This will be similar for all index tests, target conditions, and populations.

YES: if a study explicitly stated that all participants within a certain time frame were included; that this was done consecutively; or that a random selection was done.

NO: if it was clear that a different selection procedure was employed; for example, selection based on clinician's preference, or based on institutions.

UNCLEAR: if the selection procedure was not clear or not reported.

This will be similar for all index tests, target conditions, and populations.

YES: if a study explicitly stated that all participants came from the same group of (suspected) patients.

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews NO: if it was clear that a different selection procedure was employed for the participants depending on their COVID-19 status or SARS-CoV-2 infection status; or if only participants with SARS-CoV-2 infection were included UNCLEAR: if the selection procedure was not clear or not reported.

Studies may have excluded patients, or selected patients in such a way that they avoided including those who were difficult to diagnose or likely to be borderline. Although the inclusion and exclusion criteria will be different for the different index tests, inappropriate exclusions and inclusions will be similar for all index tests: for example, only elderly patients excluded, or children (as sampling may be more difficult). This needs to be addressed on a case-to-case basis.

YES: if a high proportion of eligible patients was included without clear selection.

NO: if a high proportion of eligible patients was excluded without providing a reason; if, in a retrospective study, participants without index test or reference standard results were excluded.

UNCLEAR: if the exclusion criteria were not reported.

Some laboratory studies may have intentionally included groups of patients in whom the accuracy was likely to differ, such as those with particularly low or high viral loads, or who had other diseases, such that the sample over-represented these groups. This needs to be addressed on a caseto-case basis. Artificial spiked samples are a clear example.

YES: if samples included were likely to be representative of the spectrum of disease.

NO: if the study oversampled patients with particular characteristics likely to affect estimates of accuracy.

UNCLEAR: if the exclusion criteria were not reported.

HIGH: if one or more signalling questions were answered with NO, as any deviation from the selection process may lead to bias.

LOW: if all signalling questions were answered with YES.

UNCLEAR: all other instances.

Is there concern that the included participants do not match the review question?

HIGH: for two-group studies that included healthy or other disease controls, whether pre-pandemic or contemporaneous; studies that only included people with COVID-19 (whether reverse transcription polymerase chain reaction (RT-PCR)-confirmed only, participants meeting official guideline criteria);

LOW: for single-group studies recruiting participants with signs and symptoms of COVID-19; or for two-group studies where control groups suspected of COVID-19 were separately recruited.

UNCLEAR: if a description about the participants was lacking.

YES: if blinding was explicitly stated or index test was recorded before the results from the reference standard were available.

NO: if it was explicitly stated that the index test results were interpreted with knowledge of the results of the reference standard.

UNCLEAR: if blinding was unclearly reported.

YES: if the test was dichotomous by nature, or if the threshold was stated in the methods section, or if study authors stated that the threshold as recommended by the manufacturer was used.

NO: if a receiver operating characteristic curve was drawn or multiple threshold reported in the results section; and the final result was based on one of these thresholds. Cochrane Database of Systematic Reviews UNCLEAR: if threshold selection was not clearly reported.

HIGH: if one or more signalling questions were answered with NO, as even in a laboratory situation knowledge of the reference standard may lead to bias.

LOW: if all signalling questions were answered with YES.

UNCLEAR: all other instances.

Is there concern that the index test, its conduct, or interpretation differ from the review question?

For evaluations of laboratory-based tests, HIGH: if tests were built in-house, or if commercially available tests using SARS-Cov antigens instead of SARS-CoV-2-specific antigens.

LOW: most other laboratory-evaluations UNCLEAR: name of the test was withheld For evaluations of lateral flow assays, HIGH: if tests were built in-house; if only serum or plasma instead of fingerprick or whole blood samples were used; if test evaluated in laboratory settings rather than at the point of care LOW: commercially available tests, using whole blood or fingerprick samples, and that were conducted in the intended setting for the test (i.e. point-of-care).

UNCLEAR: name of the test was withheld; mixed sample types; or did not report the evaluation setting

Is the reference standard likely to correctly classify the target condition?

We will define acceptable reference standards using a consensus process once the list of reference standards that have been used has been obtained from the eligible studies.

For COVID-19 cases YES: RT-PCR; confirmed or suspected case using official criteria (WHO, CDC) or a clearly set out combination of signs/symptoms/exposure. UNCLEAR: all other instances.

Is there concern that the target condition as defined by the reference standard does not match the review question?

Applicability was judged primarily on the definition of disease-positive.

HIGH: if RT-PCR alone used to define cases LOW: if clinical criteria, including RT-PCR, were used to define cases, regardless of whether official criteria were used, as long as the criteria were explicitly described.

UNCLEAR: if definition of COVID-19 cases was not provided, including if some clinically diagnosed cases were included but the clinical criteria used were not described.

Did all participants receive the same reference standard?

YES: if all participants received the same reference standard (clearly no differential verification). 

This Appendix includes two tables. Please note that square brackets indicate di erent tests within one study.

1. Table A . Single-group studies estimating sensitivity (and specificity) 2. Table B . Two-group or more studies estimating sensitivity and specificity COVID-19-suspected cases presenting at A&E with fever and respiratory syndrome (n = 50, including 38 RT-PCR-positive);

• 2 x RT-PCR-negative required to rule out disease (Additional groups reported in Cassaniti 2020 (A) 

Wan 2020 [A] [A] and [B] laboratory [A] IIFT (EUROIMMUN) [B] In-house ELISA [A] and [B] both SARS-CoV Cochrane Database of Systematic Reviews Appendix 11. Results of all studies across all time periods Cochrane Database of Systematic Reviews Malcolm Price: none known Sabine Dittrich: is employed by FIND with funding from DFID and Australian Aid. FIND is a global non-for profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND's role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID-19. .FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know-how, equipment/reagents, and contribute through unrestricted donations as per FIND policy and external SAC review.

Devy Emperador: is employed by FIND with funding from DFID and KFW. FIND is a global non-for profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND's role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID-19. .FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know-how, equipment/reagents, and contribute through unrestricted donations as per FIND policy and external SAC review. 

As we explained in the review, due to poor reporting, we were unable to identify studies that evaluated the test in patients who were symptomatic (active disease) separately from those who had recovered from their symptoms (convalescent). Our stratification of results according to days since onset of symptoms will in part be related to these categorisations.

We planned to check the following websites for eligible index tests, however these did not prove to be very accessible or easy to use and, a er initial review, were not further considered:

• National Institute for Health Research (NIHR) Innovation Observatory (www.io.nihr.ac.uk/) • www.rapidmicrobiology.com/test-method/testing-for-the-wuhan-coronavirus-a-k-a-covid-19-sars-cov-2-and-2019-ncov

We planned to check the following evidence repository for additional eligible studies however, the EPPI-Centre and Norwegian Institute of Public Health resources proved to be more accessible therefore we decided to prioritise our other sources of evidence.

• Meta-evidence (meta-evidence.co.uk/the-role-of-evidence-synthesis-in-covid19/)

QUADAS-2 (Whiting 2011), item "Was there an appropriate interval between index test(s) and reference standard?" was dropped from assessment because for antibody tests, the body's immune response to SARS-CoV-2 infection tends to increase over time such that the time between confirmation of the presence of SARS-CoV-2 an the index test is less relevant than the time from symptom onset to the application of the index test.

Antibodies 

Correlation of Chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Diagnosis of SARS-CoV-2 infection and COVID-19: accuracy of signs and symptoms; molecular, antigen, and antibody tests; and routine laboratory markers

CGIA: colloidal gold immunoassay; CI: confidence interval; CLIA: chemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; FIA: fluorescence immunoassay

CGIA: colloidal gold immunoassay; CI: confidence interval; CLIA: chemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; FIA: fluorescence immunoassay

Dynamiker Biotech 2019-nCOV IgG/IgM Rapid Test [E] CTK Biotech -OnSiteTM COV-ID-19 IgG/IgM Rapid Test [F] Autobio Diagnostics Anti-SARS-CoV-2 Rapid Test

Artron Labs Coronavirus Diseases 2019 (COVID-19) IgM/IgG Antibody Test

Acro Biotech 2019-nCoV IgG/ IgM Rapid Test Cassette

Hangzhou All test 2019-nCoV IgG/IgM Rapid Test Cassette

Visual line change) Serum Day 7 to ≥ 21 Yes Li 2020a LFA CGIA

IgG (coloured line) Serum, plasma Not stated

RLU 336697) (threshold set using ROC analysis)

JJD co-ordinated contributions from the co-authors and wrote the final dra of the review

SB screened papers against eligibility criteria. RS conducted the literature searches

SB extracted data for the review and sought additional information about papers. JJD and JDi entered data into Review Manager

René Spijker: the Dutch Cochrane Centre (DCC) has received grants for performing commissioned systematic reviews

Ada Adriano: none known Sophie Beese: none known Janine Dretzke: none known

Isobel Harris: none known Antibody tests for identification of current and past infection with SARS-CoV-2 (Review)

Copyright © 2020 The Authors

Are there concerns that the included patients and setting do not match the review question?High DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?No If a threshold was used, was it pre-specified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

To 2020a [A] (Continued) Cochrane Database of Systematic Reviews Index tests 2 tests evaluated, this entry (Wang 2020a [A] ) refers to test [A] A. SARS-CoV-2 IgM detection kit CGIA (Beijing Hotgen Biotechnology Co., Beijing, China) (POC test, evaluation appears to be laboratory-based) B Index tests 3 tests evaluated, this entry (Zhong 2020 [C] ) refers to test [C] Both laboratory-based evaluations to detect IgM and IgG A. ELISA using N gene of the SARS-CoV-2 cloned into a pET28a vector (rN-based assay) B ELISA using S gene cloned into a pMFcIg vector-based (rS-based assay) C. CLIA (not clearly described; potentially uses both of above described antigens) Thesholds defined retrospectively in regard to optimal cut-o on ROC curve Mixed or unclear 6 (11%)

Recruitment structure Single group, both COVID-19 and non-COVID-19 cases 6 (11%) 

The following information is taken from the university of Bern website (see: ispmbern.github.io/covid-19/living-review/ collectingdata.html).The register is updated daily and CSV file downloads are made available.

From 1 April 2020, we will retrieve the curated BioRxiv/MedRxiv dataset (connect.medrxiv.org/relate/content/181). With the kind support of the Public Health & Primary Care Library PHC (www.unibe.ch/university/services/university_library/ faculty_libraries/medicine/public_health_amp_primary_care_library_phc/index_eng.html), and following guidance of the Medical Library Association (www.mlanet.org/p/cm/ld/fid=1713). 

Age ( (6) 

Adams 2020 [A] [A] a Laboratory [B] to [J] LFAs [A] ELISA (In-house) [B] to [J] name withheld [A] tri S-based [B] to [J] details withheld [A] IgG (> 0.4) and IgM (IgM > 0.07) (set in study) [B] and [C] not known [D] Laboratory [A] and [B] in-house ELISA [C] Lassauniere 2020 [B] ; Lassauniere 2020 [C] Anti-SARS-CoV-2 IgG (EI 2668-9601 G)Anti-SARS-CoV-2 IgA (EI 2606-9601 A)Lippi 2020 [B] No product code reported; "Anti-SARS-CoV-2 IgA and IgG … ELISAs; Euroimmun AG, Lübeck, Germany" 

Review first published: Issue 6, 2020